Top-Rated StocksTop-Rated Phreesia Stock Price, News & Analysis (NYSE:PHR) $18.03 +0.16 (+0.90%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$17.49▼$18.2550-Day Range$12.40▼$18.8952-Week Range$12.05▼$40.00Volume836,082 shsAverage Volume657,913 shsMarket Capitalization$1.00 billionP/E RatioN/ADividend YieldN/APrice Target$34.31 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Phreesia MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside90.3% Upside$34.31 Price TargetShort InterestHealthy3.69% of Shares Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.09Based on 24 Articles This WeekInsider TradingSelling Shares$567,877 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.54) to ($1.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.85 out of 5 starsMedical Sector46th out of 946 stocksBusiness Services, Not Elsewhere Classified Industry8th out of 81 stocks 4.4 Analyst's Opinion Consensus RatingPhreesia has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.31, Phreesia has a forecasted upside of 90.3% from its current price of $18.03.Amount of Analyst CoveragePhreesia has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.69% of the outstanding shares of Phreesia have been sold short.Short Interest Ratio / Days to CoverPhreesia has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Phreesia has recently decreased by 13.14%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPhreesia does not currently pay a dividend.Dividend GrowthPhreesia does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePhreesia has received a 60.31% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Patient flow management systems", "Health care management software", and "Personal health record software" products. See details.Environmental SustainabilityThe Environmental Impact score for Phreesia is -0.60. Previous Next 2.3 News and Social Media Coverage News SentimentPhreesia has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Phreesia this week, compared to 3 articles on an average week.Search Interest1 people have searched for PHR on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Phreesia to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Phreesia insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $567,877.00 in company stock.Percentage Held by InsidersOnly 5.80% of the stock of Phreesia is held by insiders.Percentage Held by Institutions94.37% of the stock of Phreesia is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Phreesia are expected to grow in the coming year, from ($2.54) to ($1.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phreesia is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phreesia is -6.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPhreesia has a P/B Ratio of 3.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Phreesia Stock (NYSE:PHR)Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Wilmington, Delaware.Read More PHR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHR Stock News HeadlinesDecember 8, 2023 | finance.yahoo.comPhreesia, Inc. (NYSE:PHR) Q3 2024 Earnings Call TranscriptDecember 8, 2023 | americanbankingnews.comPhreesia (NYSE:PHR) Given New $30.00 Price Target at KeyCorpDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 8, 2023 | americanbankingnews.comPhreesia (NYSE:PHR) Given New $25.00 Price Target at Raymond JamesDecember 7, 2023 | seekingalpha.comIs Phreesia Finally Turning The Corner?December 7, 2023 | americanbankingnews.comPhreesia (NYSE:PHR) Price Target Lowered to $29.00 at Needham & Company LLCDecember 7, 2023 | americanbankingnews.comPhreesia (NYSE:PHR) Given New $28.00 Price Target at JMP SecuritiesDecember 7, 2023 | americanbankingnews.comPhreesia (NYSE:PHR) Shares Gap Up on Better-Than-Expected EarningsDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comDecember 6, 2023 | markets.businessinsider.comThis Analyst Lowers Phreesia's Price Target Despite Projecting "Plenty Of Opportunity For Upside" - Read WhyDecember 6, 2023 | businesswire.comPhreesia Announces Third Quarter Fiscal 2024 ResultsDecember 6, 2023 | marketwatch.comPhreesia Shares Rise 25% on 3Q Sales Surge, Long-Term OutlookDecember 6, 2023 | markets.businessinsider.comWhere Phreesia Stands With AnalystsDecember 6, 2023 | finance.yahoo.comQ3 2024 Phreesia Inc Earnings CallDecember 5, 2023 | benzinga.comRecap: Phreesia Q3 EarningsDecember 5, 2023 | msn.comHere's What Key Metrics Tell Us About Phreesia (PHR) Q3 EarningsDecember 5, 2023 | msn.comPhreesia GAAP EPS of -$0.58 beats by $0.10, revenue of $91.62M beats by $1.82MDecember 5, 2023 | finance.yahoo.comPhreesia Inc (PHR) Reports Revenue Growth and Narrowed Net Loss in Q3 Fiscal 2024December 4, 2023 | msn.comPhreesia Q3 2024 Earnings PreviewDecember 4, 2023 | markets.businessinsider.comPhreesia earnings preview: what Wall Street is expectingDecember 4, 2023 | benzinga.comEarnings Preview For PhreesiaDecember 1, 2023 | msn.comPhreesia says PAM measure added to Medicare incentive systemDecember 1, 2023 | finance.yahoo.comCMS Includes the Patient Activation Measure in its Merit-Based Incentive Payment System Starting in 2024November 16, 2023 | finance.yahoo.comHere’s Why Phreesia (PHR) Declined in Q3November 11, 2023 | morningstar.comPhreesia Inc PHRNovember 8, 2023 | finance.yahoo.comPhreesia Achieves HITRUST Risk-Based, 2-Year Certification Demonstrating the Highest Level of Information Protection AssuranceNovember 6, 2023 | bizjournals.comVacancy rates remain high for Triangle office supplySee More Headlines Receive PHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phreesia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/06/2023Today12/08/2023Fiscal Year End1/31/2024Next Earnings (Estimated)3/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Business services, not elsewhere classified Sub-IndustryN/A SectorMedical Current SymbolNYSE:PHR CUSIPN/A CIK1412408 Webwww.phreesia.com Phone(888) 654-7473Fax646-607-1776Employees1,546Year FoundedN/APrice Target and Rating Average Stock Price Target$34.31 High Stock Price Target$43.00 Low Stock Price Target$25.00 Potential Upside/Downside+90.3%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-176,150,000.00 Net Margins-47.75% Pretax Margin-47.44% Return on Equity-54.52% Return on Assets-41.73% Debt Debt-to-Equity Ratio0.03 Current Ratio2.58 Quick Ratio2.58 Sales & Book Value Annual Sales$280.91 million Price / Sales3.54 Cash FlowN/A Price / Cash FlowN/A Book Value$5.46 per share Price / Book3.30Miscellaneous Outstanding Shares55,210,000Free Float52,007,000Market Cap$995.44 million OptionableNot Optionable Beta0.84 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Chaim Indig (Age 44)Co-Founder, CEO & Director Comp: $515kMr. Evan Roberts (Age 44)Co-Founder & COO Comp: $400kMr. Michael J. Davidoff (Age 50)Senior Vice President of Payer Solutions Comp: $350kMr. David Linetsky (Age 43)Senior Vice President of Life Sciences Comp: $551.64kMr. Balaji Gandhi (Age 49)Chief Financial Officer Ms. Janet M. Gunzburg (Age 57)VP, Principal Accounting Officer & Controller Mr. Daniel Nathan (Age 46)Chief Technology Officer Ms. Allison C. Hoffman (Age 52)General Counsel & Secretary Comp: $418.96kMs. Maureen McKinneyVice President of Corporate CommunicationsMs. Kharen HauckVice President of MarketingMore ExecutivesKey CompetitorsMultiPlanNYSE:MPLNAmerican WellNYSE:AMWLAugmedixNASDAQ:AUGXTalaris TherapeuticsNASDAQ:TALSNewAmsterdam PharmaNASDAQ:NAMSView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 3,831 shares on 11/24/2023Ownership: 0.050%Walleye Capital LLCBought 1,300 shares on 11/21/2023Ownership: 0.000%Walleye Trading LLCBought 800 shares on 11/21/2023Ownership: 0.000%TimesSquare Capital Management LLCBought 55,793 shares on 11/17/2023Ownership: 1.402%Spouting Rock Asset Management LLCBought 1,895 shares on 11/16/2023Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions PHR Stock Analysis - Frequently Asked Questions Should I buy or sell Phreesia stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phreesia in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" PHR shares. View PHR analyst ratings or view top-rated stocks. What is Phreesia's stock price target for 2024? 13 brokerages have issued 12-month price targets for Phreesia's shares. Their PHR share price targets range from $25.00 to $43.00. On average, they anticipate the company's stock price to reach $34.31 in the next twelve months. This suggests a possible upside of 90.3% from the stock's current price. View analysts price targets for PHR or view top-rated stocks among Wall Street analysts. How have PHR shares performed in 2023? Phreesia's stock was trading at $32.36 at the beginning of the year. Since then, PHR shares have decreased by 44.3% and is now trading at $18.03. View the best growth stocks for 2023 here. When is Phreesia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our PHR earnings forecast. How were Phreesia's earnings last quarter? Phreesia, Inc. (NYSE:PHR) posted its earnings results on Wednesday, December, 6th. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10. The business earned $91.62 million during the quarter, compared to the consensus estimate of $89.60 million. Phreesia had a negative trailing twelve-month return on equity of 54.28% and a negative net margin of 42.70%. The firm's revenue was up 25.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.76) earnings per share. What ETFs hold Phreesia's stock? ETFs with the largest weight of Phreesia (NYSE:PHR) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Fidelity Digital Health ETF (FDHT), Fidelity Disruptive Medicine ETF (FMED) and iShares U.S. Healthcare Providers ETF (IHF) and What is Chaim Indig's approval rating as Phreesia's CEO? 172 employees have rated Phreesia Chief Executive Officer Chaim Indig on Glassdoor.com. Chaim Indig has an approval rating of 73% among the company's employees. What other stocks do shareholders of Phreesia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Phreesia investors own include Fastly (FSLY), Zscaler (ZS), Okta (OKTA), DocuSign (DOCU), HealthEquity (HQY), Block (SQ), Appian (APPN), Walt Disney (DIS), Globant (GLOB) and Invitae (NVTA). When did Phreesia IPO? (PHR) raised $127 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 7,800,000 shares at $15.00-$17.62 per share. J.P. Morgan, Wells Fargo Securities, William Blair, Allen & Company and Piper Jaffray served as the underwriters for the IPO. Who are Phreesia's major shareholders? Phreesia's stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (14.23%), Brown Advisory Inc. (5.86%), Jennison Associates LLC (4.05%), Rock Springs Capital Management LP (3.22%), Riverbridge Partners LLC (1.56%) and Loomis Sayles & Co. L P (1.48%). Insiders that own company stock include Allison C Hoffman, Allison C Hoffman, Amy Beth Vanduyn, Balaji Gandhi, Chaim Indig, Cheryl Pegus, David Linetsky, Edward L Cahill, Edward L Cahill, Evan Roberts, Gillian Munson, Janet Gunzburg, Mark Douglas Smith, Michael J Davidoff, Michael Weintraub, Randy Rasmussen and Thomas Altier. View institutional ownership trends. How do I buy shares of Phreesia? Shares of PHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSE:PHR) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phreesia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.